Expanded Access Program of Ponatinib

NCT01592136 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Interventions

DRUG: ponatinib

Sponsor

Ariad Pharmaceuticals